HCRP‑1 alleviates the malignant phenotype and angiogenesis of oral squamous cell carcinoma cells via the downregulation of the EGFR/STAT3 signaling pathway

Chen,Yang; Hou,Li

doi:10.3892/ol.2022.13507

HCRP‑1 alleviates the malignant phenotype and angiogenesis of oral squamous cell carcinoma cells via the downregulation of the EGFR/STAT3 signaling pathway

Authors:
- Yang Chen
- Li Hou
View Affiliations

Affiliations: Clinic of Dental Experts, Xi'an Savaid Stomatology Hospital, University of Chinese Academy of Sciences, Xi'an, Shaanxi 710032, P.R. China, Department of Preventive Dentistry, Nice Care Dental, Xi'an, Shaanxi 710075, P.R. China
Published online on: September 16, 2022 https://doi.org/10.3892/ol.2022.13507
Article Number: 387
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has previously been reported that human hepatocellular carcinoma‑related protein 1 (HCRP‑1), which is a tumor suppressor gene, and epidermal growth factor receptor (EGFR) are abnormally expressed in certain solid tumors. Therefore, in the present study, the expression patterns of HCRP‑1 in oral squamous cell carcinoma (OSCC) are discussed. Moreover, the present study investigated whether HCRP‑1 regulated EGFR expression levels and its downstream effectors to further determine the regulation of tumor cell behavior. Therefore, the expression levels of HCRP‑1 in normal oral epithelial and OSCC cells were determined, and the effects of HCRP‑1 overexpression on OSCC cell proliferation, migration and invasion were assessed. Moreover, the culture medium from the different groups of OSCC cells was separately supplemented into the human umbilical vein endothelial cell (HUVEC) cultures, and the migration and angiogenesis of the HUVECs were assessed. To determine the roles of EGFR/STAT3 in the regulation of HCRP‑1, EGF and colivelin, a STAT3 agonist, were used to treat CAL‑27 cells and their effects on the cells were assessed using the aforementioned functional experiments. The results demonstrated that HCRP‑1 expression levels were downregulated in OSCC cells and that HCRP‑1 overexpression could suppress OSCC cell proliferation, migration and invasion. Moreover, the culture medium from OSCC cells overexpressing HCRP‑1 facilitated the migration and angiogenesis of HUVECs. Furthermore, HCRP‑1 was demonstrated to function in cells by regulating the EGFR/STAT3 signaling pathway. In summary, the present study indicated that HCRP‑1 alleviated the malignant phenotype and angiogenesis of OSCC cells via the downregulation of the EGFR/STAT3 signaling pathway.

View Figures

View References

1	Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE and Grandis JR: Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 6:922020. View Article : Google Scholar : PubMed/NCBI
2	Singh P, Rai A, Verma AK, Alsahli MA, Rahmani AH, Almatroodi SA, Alrumaihi F, Dev K, Sinha A, Sankhwar S and Dohare R: Survival-based biomarker module identification associated with oral squamous cell carcinoma (OSCC). Biology (Basel). 10:7602021.PubMed/NCBI
3	Romer CAE, Broglie Daeppen MA, Mueller M, Huber GF, Guesewell S and Stoeckli SJ: Long-term speech and swallowing function after primary resection and sentinel node biopsy for early oral squamous cell carcinoma. Oral Oncol. 89:127–132. 2019. View Article : Google Scholar : PubMed/NCBI
4	Jethwa AR and Khariwala SS: Tobacco-related carcinogenesis in head and neck cancer. Cancer Metastasis Rev. 36:411–423. 2017. View Article : Google Scholar : PubMed/NCBI
5	Zhu F, Yang T, Yao M, Shen T and Fang C: HNRNPA2B1, as a m⁶A reader, promotes tumorigenesis and metastasis of oral squamous cell carcinoma. Front Oncol. 11:7169212021. View Article : Google Scholar : PubMed/NCBI
6	Jin Z, Zhao X, Cui L, Xu X, Zhao Y, Younai F, Messadi D and Hu S: UBE2C promotes the progression of head and neck squamous cell carcinoma. Biochem Biophys Res Commun. 523:389–397. 2020. View Article : Google Scholar : PubMed/NCBI
7	Li X, Zhu F, Liu Z, Tang X, Han Y, Jiang J, Ma C and He Y: High expression of Rab31 confers a poor prognosis and enhances cell proliferation and invasion in oral squamous cell carcinoma. Oncol Rep. 45:1182–1192. 2021. View Article : Google Scholar : PubMed/NCBI
8	Hasegawa K, Fujii S, Matsumoto S, Tajiri Y, Kikuchi A and Kiyoshima T: YAP signaling induces PIEZO1 to promote oral squamous cell carcinoma cell proliferation. J Pathol. 253:80–93. 2021. View Article : Google Scholar : PubMed/NCBI
9	Rahimi S: HPV-related squamous cell carcinoma of oropharynx: A review. J Clin Pathol. 73:624–629. 2020. View Article : Google Scholar : PubMed/NCBI
10	Tomasich E, Topakian T, Heller G, Udovica S, Krainer M and Marhold M: Loss of HCRP1 leads to upregulation of PD-L1 via STAT3 activation and is of prognostic significance in EGFR-dependent cancer. Transl Res. 230:21–33. 2021. View Article : Google Scholar : PubMed/NCBI
11	Sun L, Lü J, Ding S, Bi D, Ding K, Niu Z and Liu P: HCRP1 regulates proliferation, invasion, and drug resistance via EGFR signaling in prostate cancer. Biomed Pharmacother. 91:202–207. 2017. View Article : Google Scholar : PubMed/NCBI
12	Yang W, Wang JG, Wang Q, Qin Y, Lin X, Zhou D, Ren K, Hou C, Xu J and Liu X: Decreased HCRP1 promotes breast cancer metastasis by enhancing EGFR phosphorylation. Biochem Biophys Res Commun. 477:222–228. 2016. View Article : Google Scholar : PubMed/NCBI
13	Xu J, Zhang X, Wang H, Ge S, Gao T, Song L, Wang X, Li H, Qin Y and Zhang Z: HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition. Biomed Pharmacother. 88:421–429. 2017. View Article : Google Scholar : PubMed/NCBI
14	Du Y, Wang P, Sun H, Yang J, Lang X, Wang Z, Zang S, Chen L, Ma J and Sun D: HCRP1 is downregulated in non-small cell lung cancer and regulates proliferation, invasion, and drug resistance. Tumour Biol. Oct 13–2016.(Epub ahead of print). View Article : Google Scholar
15	Chen F, Zhang L, Wu J, Huo F, Ren X, Zheng J and Pei D: HCRP-1 regulates EGFR-AKT-BIM-mediated anoikis resistance and serves as a prognostic marker in human colon cancer. Cell Death Dis. 9:11762018. View Article : Google Scholar : PubMed/NCBI
16	Wu Y, Yang Y and Xian YS: HCRP1 inhibits cell proliferation and invasion and promotes chemosensitivity in esophageal squamous cell carcinoma. Chem Biol Interact. 308:357–363. 2019. View Article : Google Scholar : PubMed/NCBI
17	Ferguson KM, Hu C and Lemmon MA: Insulin and epidermal growth factor receptor family members share parallel activation mechanisms. Protein Sci. 29:1331–1344. 2020. View Article : Google Scholar : PubMed/NCBI
18	Talukdar S, Emdad L, Das SK and Fisher PB: EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells. Adv Cancer Res. 147:161–188. 2020. View Article : Google Scholar : PubMed/NCBI
19	Sabbah DA, Hajjo R and Sweidan K: Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr Top Med Chem. 20:815–834. 2020. View Article : Google Scholar : PubMed/NCBI
20	Masood A, Kancha RK and Subramanian J: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib. Semin Oncol. 46:271–283. 2019. View Article : Google Scholar : PubMed/NCBI
21	Liu YC, Tsai JJ, Weng YS and Hsu FT: Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer. Biomed Pharmacother. 128:1103192020. View Article : Google Scholar : PubMed/NCBI
22	Lu S, Fan HW, Li K and Fan XD: Suppression of Elp2 prevents renal fibrosis and inflammation induced by unilateral ureter obstruction (UUO) via inactivating Stat3-regulated TGF-β1 and NF-κB pathways. Biochem Biophys Res Commun. 501:400–407. 2018. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Cheng HW, Chen YF, Wong JM, Weng CW, Chen HY, Yu SL, Chen HW, Yuan A and Chen JJ: Cancer cells increase endothelial cell tube formation and survival by activating the PI3K/Akt signalling pathway. J Exp Clin Cancer Res. 36:272017. View Article : Google Scholar : PubMed/NCBI
25	Wang Y, Dong L, Zhong H, Yang L, Li Q, Su C, Gu W and Qian Y: Extracellular vesicles (EVs) from lung adenocarcinoma cells promote human umbilical vein endothelial cell (HUVEC) angiogenesis through yes kinase-associated protein (YAP) transport. Int J Biol Sci. 15:2110–2118. 2019. View Article : Google Scholar : PubMed/NCBI
26	Shintani T, Takatsu F, Rosli SNZ, Usui E, Hamada A, Sumi K, Hayashido Y, Toratani S and Okamoto T: Eldecalcitol (ED-71), an analog of 1α,25(OH)₂D₃, inhibits the growth of squamous cell carcinoma (SCC) cells in vitro and in vivo by down-regulating expression of heparin-binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1) and FGF-2. In Vitro Cell Dev Biol Anim. 53:810–817. 2017. View Article : Google Scholar : PubMed/NCBI
27	Sciubba JJ and Larian B: Oral squamous cell carcinoma: Early detection and improved 5-year survival in 102 patients. Gen Dent. 66:e11–e16. 2018.PubMed/NCBI
28	Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, Rosenberg PS, Bray F and Gillison ML: Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 31:4550–4559. 2013. View Article : Google Scholar : PubMed/NCBI
29	Sá JO, Trino LD, Oliveira AK, Lopes AFB, Granato DC, Normando AGC, Santos ES, Neves LX, Carnielli CM and Paes Leme AF: Proteomic approaches to assist in diagnosis and prognosis of oral cancer. Expert Rev Proteomics. 18:261–284. 2021. View Article : Google Scholar : PubMed/NCBI
30	Mirza S, Hadi N, Pervaiz S, Zeb Khan S, Mokeem SA, Abduljabbar T, Al-Hamoudi N and Vohra F: Expression of HER-2/neu in oral squamous cell carcinoma. Asian Pac J Cancer Prev. 21:1465–1470. 2020. View Article : Google Scholar : PubMed/NCBI
31	Pillai J, Chincholkar T, Dixit R and Pandey M: A systematic review of proteomic biomarkers in oral squamous cell cancer. World J Surg Oncol. 19:3152021. View Article : Google Scholar : PubMed/NCBI
32	Wittekindt C, Wagner S, Sharma SJ, Würdemann N, Knuth J, Reder H and Klußmann JP: HPV-a different view on head and neck cancer. Laryngorhinootologie. 97 (Suppl 1):S48–S113. 2018.PubMed/NCBI
33	Yokokawa M, Morita KI, Oikawa Y, Oikawa Y, Kayamori K, Sakamoto K, Ikeda T and Harada H: Co-expression of EGFR and MET has a synergistic effect on the prognosis of patients with oral squamous cell carcinoma. J Oral Pathol Med. 49:235–242. 2020. View Article : Google Scholar : PubMed/NCBI
34	Chai AWY, Lim KP and Cheong SC: Translational genomics and recent advances in oral squamous cell carcinoma. Semin Cancer Biol. 61:71–83. 2020. View Article : Google Scholar : PubMed/NCBI
35	Yin P, Cui S, Liao X and Yao X: Galectin-3 blockade suppresses the growth of cetuximab-resistant human oral squamous cell carcinoma. Mol Med Rep. 24:6852021. View Article : Google Scholar : PubMed/NCBI
36	Uzawa K, Kasamatsu A, Saito T, Kita A, Sawai Y, Toeda Y, Koike K, Nakashima D, Endo Y, Shiiba M, et al: Growth suppression of human oral cancer cells by candidate agents for cetuximab-side effects. Exp Cell Res. 376:210–220. 2019. View Article : Google Scholar : PubMed/NCBI
37	Ding L, Ren J, Zhang D, Li Y, Huang X, Ji J, Hu Q, Wang H, Ni Y and Hou Y: The TLR3 agonist inhibit drug efflux and sequentially consolidates low-dose cisplatin-based chemoimmunotherapy while reducing side effects. Mol Cancer Ther. 16:1068–1079. 2017. View Article : Google Scholar : PubMed/NCBI
38	Russo A, Franchina T, Ricciardi G, Battaglia A, Picciotto M and Adamo V: Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario. Int J Mol Sci. 20:14312019. View Article : Google Scholar : PubMed/NCBI
39	Eskilsson E, Røsland GV, Solecki G, Wang Q, Harter PN, Graziani G, Verhaak RGW, Winkler F, Bjerkvig R and Miletic H: EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro Oncol. 20:743–752. 2018. View Article : Google Scholar : PubMed/NCBI
40	Tseng YK, Chen CF, Shu CW, Lee CH, Chou YT, Li YJ, Liou HH, Cheng JT, Chen CL, Ger LP and Liu PF: Effect of EGFR on SQSTM1 expression in malignancy and tumor progression of oral squamous cell carcinoma. Int J Mol Sci. 22:122262021. View Article : Google Scholar : PubMed/NCBI
41	Tanaka T, Zhou Y, Ozawa T, Okizono R, Banba A, Yamamura T, Oga E, Muraguchi A and Sakurai H: Ligand-activated epidermal growth factor receptor (EGFR) signaling governs endocytic trafficking of unliganded receptor monomers by non-canonical phosphorylation. J Biol Chem. 293:2288–2301. 2018. View Article : Google Scholar : PubMed/NCBI
42	Sun N, Zhang X, Zhang X and Kim KM: The EGF receptor inhibits the signaling of dopamine D₃ receptor through the phosphorylation of GRK2 on tyrosine residues. Biochem Biophys Res Commun. 489:515–522. 2017. View Article : Google Scholar : PubMed/NCBI